CENTER FOR DISEASE ANALYSIS FOUNDATION, INC.

Financial Statements

For the Years Ended December 31, 2023 and 2022

INDEX TO FINANCIAL STATEMENTS

Ryan, Gunsauls & O'Donnell, LLC
Certified Public Accountants

INDEPENDENT ACCOUNTANTS' REVIEW REPORT

To the Board of Directors
Center for Disease Analysis Foundation, Inc.
Lafayette, CO

We have reviewed the accompanying financial statements of Center for Disease Analysis Foundation, Inc. (a nonprofit organization), which comprise the statement of financial position as of December 31, 2023, and the related statements of activities and changes in net assets, functional expenses and cash flows for the year then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

Accountants' Responsibility

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

We are required to be independent of Center for Disease Analysis Foundation, Inc. and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our review.

Accountants' Conclusion

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

5590 East Yale Avenue, Suite 201 | Denver, Colorado 80222
Tel 303.758.5558 | Fax 303.756.1741 | www.rgo-cpa.com

Summarized Comparative Information

We previously reviewed Center for Disease Analysis Foundation, Inc.'s 2022 financial statements and in our conclusion dated May 19, 2023, stated that based on our review, we were not aware of any material modifications that should be made to the 2022 financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America. We are not aware of any material modifications that should be made to the summarized comparative information presented herein as of and for the year ended December 31, 2022, for it to be consistent with the reviewed financial statements from which it has been derived.

Ryan, Gunsauls & O'Donnell, LLC

Denver, Colorado
August 2, 2024

CENTER FOR DISEASE ANALYSIS FOUNDATION, INC.

Statement of Financial Position

December 31, 2023 and 2022

ASSETS

		2023		2022
Current assets:				
Cash and cash equivalents	$	2,666,400	$	2,869,854
Restricted cash and cash equivalents		4,183,470		630,569
Accounts receivable		5,673		6,926
Prepaid expense		8,541		7,587
Total current assets		**6,864,084**		**3,514,936**
Right-of-use asset, net		**88,410**		**156,515**
Note receivable		**3,779**		**-**
Total assets	**$**	**6,956,273**	**$**	**3,671,451**

LIABILITIES AND NET ASSETS

		2023		2022
Current liabilities:				
Accounts payable	$	23,113	$	3,803
Accrued liabilities		21,436		20,524
Deferred revenue		3,929,113		91,371
Current portion of lease liability-operating lease		69,537		26,635
Total current liabilities		**4,043,199**		**142,333**
Non-current liabilities:				
Long-term portion of lease liability-operating leases		18,873		129,880
Total non-current liabilities		**18,873**		**129,880**
Total liabilities		**4,062,072**		**272,213**
Net assets:				
Without donor restrictions		2,780,430		3,098,249
With donor restrictions		113,771		300,989
Total net assets		**2,894,201**		**3,399,238**
Total liabilities and net assets	**$**	**6,956,273**	**$**	**3,671,451**

See accompanying independent accountants' review report and notes to financial statements.

CENTER FOR DISEASE ANALYSIS FOUNDATION, INC.
Statement of Activities and Changes in Net Assets
For the Year Ended December 31, 2023 with Summarized Comparative Totals for 2022

	Without donor restrictions	With donor restrictions	2023 Total	2022 (Summarized)
Revenue and support:				
Revenues from contracts	$ 596,445	$ -	$ 596,445	$ 1,080,785
Support revenue	139,130	-	139,130	157,936
Released from restriction	187,218	(187,218)	-	-
Total revenue and support	**922,793**	**(187,218)**	**735,575**	**1,238,721**
Expenses:				
Program services	1,183,517	-	1,183,517	1,131,173
General and administrative	183,494	-	183,494	182,430
Fundraising	10,244	-	10,244	10,035
Total expenses	**1,377,255**	**-**	**1,377,255**	**1,323,638**
Change in net assets from operations	**(454,462)**	**(187,218)**	**(641,680)**	**(84,917)**
Other income (expense):				
Interest income	149,088	-	149,088	327
Miscellaneous expense	(12,445)	-	(12,445)	-
Total other income	**136,643**	**-**	**136,643**	**327**
Change in net assets	**(317,819)**	**(187,218)**	**(505,037)**	**(84,590)**
Net assets, beginning of year	3,098,249	300,989	3,399,238	**3,672,228**
Prior period adjustment (Note 12)	-	-	-	**(188,400)**
Net assets, beginning of year, restated	3,098,249	300,989	3,399,238	**3,483,828**
Net assets, end of year	**$ 2,780,430**	**$ 113,771**	**$ 2,894,201**	**$ 3,399,238**

See accompanying independent accountants' review report and notes to financial statements.

CENTER FOR DISEASE ANALYSIS FOUNDATION, INC.
Statement of Functional Expenses
For the Year Ended December 31, 2023 with Summarized Comparative Totals for 2022

	Program services	General and administrative	Fundraising	**2023 Total**	**2022 (Summarized)**
Salaries and wages	$ 438,547	$ 73,544	$ 2,875	$ **514,966**	**$ 570,982**
Office expense	327,577	27,366	134	**355,077**	**188,202**
Employee benefits	78,384	41,209	2,122	**121,715**	**154,761**
Grants and contributions	94,353	-	-	**94,353**	**72,850**
Professional fees	65,141	21,234	-	**86,375**	**61,047**
GPRO	59,650	-	-	**59,650**	**136,345**
Travel, meals, and entertainment	46,874	-	-	**46,874**	**41,140**
Occupancy costs	34,470	3,639	4,903	**43,012**	**41,321**
Payroll taxes	34,507	5,892	210	**40,609**	**45,095**
Advertising	-	5,871	-	**5,871**	**399**
Insurance	-	4,739	-	**4,739**	**5,433**
Conferences	4,014	-	-	**4,014**	**6,063**
Total expenses	**$ 1,183,517**	**$ 183,494**	**$ 10,244**	**$ 1,377,255**	**$ 1,323,638**
Percent of total expenses	**85.9%**	**13.4%**	**0.7%**	**100.0%**	**100.0%**

See accompanying independent accountants' review report and notes to financial statements.

CENTER FOR DISEASE ANALYSIS FOUNDATION, INC.
Statement of Cash Flows
For the Years Ended December 31, 2023 and 2022

		2023		2022
Cash flows from operating activities:				
Change in net assets	$	(505,037)	$	(84,590)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:				
Amortization of right-of-use asset - operating		(68,105)		24,874
(Increase) decrease in operating assets:				
Accounts receivable		1,253		(6,426)
Promises to give		-		-
Prepaid expense		(954)		(7,587)
Increase (decrease) in operating liabilities:				
Accounts payable		19,310		(3,588)
Accrued expenses		912		(800)
Operating lease liabilities		68,105		(24,874)
Deferred revenue		3,837,742		91,371
Net cash provided by (used in) operating activities		**3,353,226**		**(11,620)**
Cash flows from investing activities:				
Advances on note receivable		(3,779)		-
Net cash used in investing activities		**(3,779)**		**-**
Net change in cash and cash equivalents		**3,349,447**		**(11,620)**
Cash, cash equivalents, restricted cash, and restricted cash equivalents, beginning of year		3,500,423		3,512,043
Total cash, cash equivalents, restricted cash, and restricted cash equivalents, end of year	$	**6,849,870**	$	**3,500,423**
Cash and cash equivalents		2,666,400		2,869,854
Restricted cash and cash equivalents		4,183,470		630,569
Total cash, cash equivalents, restricted cash, and restricted cash equivalents	$	**6,849,870**	$	**3,500,423**
Supplemental disclosure of noncash activity:				
Operating lease obligation	$	-	$	181,389

See accompanying independent accountants' review report and notes to financial statements.

Note 1: Foundation and Nature of Activities

Center for Disease Analysis Foundation, Inc. (the Foundation), a Colorado nonprofit corporation, was formed in 2013 and became active in 2016. Its mission is to eliminate worldwide suffering, adverse societal impact, and mortality caused by preventable, treatable diseases. Its vision is to accelerate hepatitis B and C elimination through verified epidemiological data, disease burden and economic impact modeling, intervention strategies, access to affordable diagnostics and treatments, innovative financing, and knowledge-sharing partnerships.

The financial statements included herein reflect the operations of Center for Disease Analysis Foundation, Inc. and its wholly owned subsidiary, CDAF Unipessoal LDA, beginning in 2023. The Foundation loaned money to CDAF Unipessoal LDA, during 2023 as start up funds. There is no other activity to consolidate with the Foundation's financial statements as of year-end. See details for the note receivable in Note 2 below.

Note 2: Summary of Significant Accounting Policies

Basis of Presentation

The financial statements have been prepared in accordance with U.S. GAAP, which requires the Foundation to report information regarding its financial position and activities according to the following net asset classifications:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Foundation. These net assets may be used at the discretion of the Foundation's management and the board of directors.

Net assets with donor restrictions – Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by passage of time. Other donor restrictions are perpetual in nature, where by the donor has stipulated the funds be maintained in perpetuity.

Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statements of activities.

Basis of Accounting

The Foundation's financial statements have been prepared using the accrual basis of accounting, and accordingly reflect all significant receivables, payables and other liabilities.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.

Note 2: Summary of Significant Accounting Policies, continued

Fair Value of Financial Statements

Cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and deferred revenue are reflected in the financial statements at fair value because of the short-term maturity of those instruments.

Cash and Cash Equivalents

The Foundation considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Restricted Cash and Cash Equivalents

Restricted cash is related to grant agreements that requires the Foundation to segregate the cash received for programs from operating cash. As of December 31, 2023 and 2022, the balance of restricted cash was $4,183,470 and $630,569, respectively.

Accounts Receivable

Accounts receivable includes amounts the Foundation expects to collect from outstanding balances from contracts. Management provides for probable uncollectible amounts through a provision for bad debt expense and an adjustment to valuation allowance based on its assessment of the current status of individual accounts. Balances still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation and a credit to accounts receivable. Total accounts receivable from contracted services were $5,673 and $6,926 for years ended December 31, 2023 and 2022, respectively.

Note Receivable

The note receivable consists of the balance of a loan provided to CDAF Unipessoal LDA, to begin operations. The balance of the loan of $3,779 is presented as a note receivable as it is due back to the Foundation in full by June 29, 2026, bearing no interest.

Deferred Revenue

Deferred revenue consists of a related party subcontract with the Foundation and a contract with a third party. Both contracts provide services related to the Foundation's mission and will be recognized as revenue when earned in 2024 and 2023, respectively. As of December 31, 2023 and 2022, deferred revenues were $3,929,113 and $91,371, respectively.

Public Support and Contributions

Public support and contributions received are recorded as revenues and net assets with or without donor restrictions, depending on the existence and nature of any donor restrictions or by law. In general, grants received by the Foundation are considered contributions.

Public support and contributions are considered to be available for unrestricted use unless specifically restricted by the donor. Amounts received that are restricted by the donor for future

Note 2: Summary of Significant Accounting Policies, continued

periods or for specific purposes are reported as increases in net assets with donor restrictions. When a restriction is fulfilled, (that is, when a stipulated time restriction ends or the purpose of restriction is accomplished), net assets with donor restrictions are reclassified and reported in the statements of activities as net assets without donor restrictions. However, if a restriction is fulfilled in the same period in which the contribution is received, the support is reported as net assets without donor restrictions.

Revenue Recognition

In accordance with ASC Sub-Topic 958-605, *Revenue Recognition*, the Foundation must determine whether a contribution (or a promise) is conditional or unconditional for transactions deemed to be a contribution. A contribution is considered to be a conditional contribution if an agreement includes a barrier that must be overcome and either a right of release or a promise to transfer assets exist. Indicators of a barrier include a measurable performance-related barrier or other measurable barrier, a stipulation that limits discretion by the recipient on the conduct of an activity, and stipulations that are related to the purpose of an agreement. Topic 958 prescribes that the Foundation should not consider probability of compliance with the barrier when determining if such contributions are conditional and should be reported as conditional contribution liability until such conditions are met. At December 31, 2023 and 2022, the Foundation did not have any conditional contribution liabilities.

Functional Allocation of Expenses

The costs of providing various programs and other activities have been summarized on a functional basis in the statements of activities. The statements of functional expenses present the natural classification detail of expenses by function. Indirect expenses are allocated to program and supporting services on the basis of the function and areas benefited and use of the assets. All other costs can be specifically identified with a particular function and are charged directly to that function. Expenses as presented in the statements of functional expenses are allocated using the specific identification method based on the coding of each invoice where ever possible. For expenses that cannot be directly allocated based on the purpose, the expense is allocated based on the percentage formula determined by the amount of time management spent on program, administrative, and fundraising activities.

Income Taxes

The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (the Code) and the Colorado Income Tax Act of 1964 (as amended). As a charitable foundation, only unrelated business income, as defined by Section 512(a)(1) of the Code, is subject to federal income tax. The Foundation had no unrelated business income for the years ended December 31, 2023 and 2022.

The Foundation has evaluated its tax positions for all open tax years. Currently, the years open for tax authority examination are 2020 through 2022 for federal purposes. However, the Foundation is not currently under audit nor has it been contacted by any taxing authority. Based on the evaluation of the Foundation’s tax positions, management believes all tax positions taken would be upheld under an examination. Therefore, no provision for the effects of uncertain tax positions have been recorded for the years ended December 31, 2023 and 2022.

Note 2: Summary of Significant Accounting Policies, continued

Risks and Uncertainties

In order to carry out its mission in the future, the Foundation must increase both the number of donors and the dollar amount of grant and contribution revenue, in addition to selling services and products. Management is actively soliciting grants from new donors, but there is a risk that the additional revenue will be insufficient to allow the Foundation to continue its work indefinitely.

The Foundation sells program services and medical products related to its mission. The medical products sold by the Foundation carry potential liability to the Foundation should they harm recipients or fail to perform as anticipated. The Foundation mitigates this risk by selling only products approved by regulatory agencies in each country.

Comparative Financial information

The financial statements include certain prior year summarized comparative information in total but not by class. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. GAAP. Accordingly, such information should be read in conjunction with the Foundation's financial statements for the year ended December 31, 2022, from which the summarized information was derived.

New Accounting Standards

In February 2016, FASB issued ASU No. 2016-02, *Leases* (Topic 842). FASB ASC 842 supersedes the lease requirements in FASB ASC 840. Under FASB ASC 842, lessees are required to recognize assets and liabilities on the statements of financial position for most leases and provide enhanced disclosures. The Foundation adopted FASB ASC 842, with a date of initial application of January 1, 2022, by applying the modified retrospective transition approach and using the additional (and optional) transition method provided by ASU No. 2018-11, *Leases* (Topic 842): Targeted Improvements. The Foundation did not restate prior comparative periods as presented under FASB ASC 840 and instead evaluated whether a cumulative effect adjustment to retained earnings as of January 1, 2022, was necessary for the cumulative impact of adoption of FASB ASC 842.

The most significant effects of adopting FASB ASC 842 was the recognition of $181,389 of operating lease right-of-use (ROU) assets and a total of $181,389 of current and long-term operating lease liabilities on the statements of financial position as of January 1, 2022. No cumulative effect adjustment to retained earnings as of January 1, 2022, was necessary. FASB ASC 842 did not have a significant effect on the results of operations or cash flows for the year ended December 31, 2022. As part of the transition, the Foundation implemented new internal controls and key system functionality to enable the preparation of financial information on adoption and elected to apply the following practical expedients: Package of practical expedients:

- Election not to reassess whether any expired or existing contracts are or contain leases
- Election not to reassess the lease classification for any expired or existing leases
- Election not to reassess initial direct costs on any existing leases

In June 2016, FASB issued ASU No. 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*, as amended, also known as Current Expected Credit Losses (CECL). This ASU requires organizations to measure all expected credit losses for financial instruments held at the reporting date and replaces the previous allowance for

Note 2: Summary of Significant Accounting Policies, continued

New Accounting Standards, continued

loan and lease losses. The ASU is effective for annual periods beginning after December 15, 2022. The Foundation adopted this ASU for the year ended December 31, 2023, using a modified-retrospective transition method, with a cumulative-effect adjustment to net assets, if necessary.

Note 3: Availability and Liquidity

The following represents the Foundation's financial resources at December 31:

	2023	2022
Financial assets at year-end:		
Cash and cash equivalents	$ 2,666,400	$ 2,869,854
Restricted cash and cash equivalents	4,183,470	630,569
Accounts receivable	5,673	6,926
Total financial assets	6,855,543	3,507,349
Less amounts not available to be used within one year:		
Restricted cash and cash equivalents	4,183,470	630,569
Total amounts not available	4,183,470	630,569
Financial assets available to meet general expenditures over the next twelve months	$ 2,672,073	$ 2,876,780

The Foundation maintains financial assets to meet 90 days of operating expenses. The Foundation does not have any borrowing arrangements to cover operating short falls, but has established relationships that could result in short-term borrowing.

Note 4: Off Balance Sheet Credit Risk

The Foundation places its cash receipts and investments with financial institutions and attempts to limit the amount of credit exposure to the Foundation. At December 31, 2023 and 2022 and on occasion throughout the year, the Foundation's cash on deposit with its financial services providers may have exceeded the insurance limit of $250,000 per depositor, per institution established by the Federal Deposit Insurance Corporation (FDIC). The excess amounts at December 31, 2023 and 2022 were $504,020 and $3,234,026, respectively. The Foundation has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.

Note 5: Restrictions on Net Assets

As of December 31, the following net assets were classified as donor restricted:

	2023	2022
John C Martin Foundation	$ 113,771	$ 300,989
	$ 113,771	$ 300,989

Note 6: Center for Disease Analysis, LLC – Related Party

One of the Foundation's officers owns a for-profit business called Center for Disease Analysis, LLC (the LLC), a public health firm with expertise in epidemiology and disease modeling that studies complex and poorly understood diseases and publishes results to help inform the community at large and support decision making. The Foundation was established to take over the LLC's work because the mission was more applicable to a not-for-profit organization. Accordingly, effective December 1, 2017, the LLC transferred all its employees to the Foundation except for a part-time management position. The LLC will continue until all programs and contracts have been transferred to the Foundation.

Note 7: Related Party Transactions

The Foundation subleases office space from the LLC under a lease through November 2021. The original lease was extended and goes through January 31, 2027. The lease provides that the Foundation will pay operating expenses identified as triple net expenses in the lease agreement, but no rent expense. The lease was amended in early 2024 with a term of March 1, 2024 through March 31, 2025, with monthly payments of $8,567. The LLC allows the Foundation to use its office equipment and furnishings.

The Foundation's founder and managing director, is also the beneficiary of CDAF Unipessoal LDA. The Foundation provided $15,000 CDAF Unipessoal LDA and paid expenses of $11,221 on behalf of CDAF Unipessoal LDA. The remaining balance of $3,779 is reported as a note receivable that is due back to the Foundation.

The Foundation employs family members of the Foundation's officer. Total wages were $189,808 and $167,910 for the years ended December 31, 2023 and 2022, respectively.

Note 8: Recognition of Revenue from Contracts

The Foundation recognizes revenue in accordance with U.S. GAAP, when all of the following conditions are satisfied:

- There is persuasive evidence that an arrangement exists;
- The product has been delivered or the services performed;
- The amount of fees to be paid by members and customers are fixed or determinable;
- The collection of fees is reasonably assured.

The Foundation recognizes revenues based upon the satisfaction of the performance of services as determined in contracts with members and program participants. Determining whether and when these criteria have been satisfied involved exercising judgment and using estimates and assumptions that can have a significant impact on the timing and amount of revenue that the Foundation recognizes.

Description of Program Activities

The Foundation provides various program activities under specific projects. The projects include analyzing the infection rates, disease costs, and long-term impacts of hepatitis on countries globally.

Note 8: Recognition of Revenue from Contracts, continued

Revenue Recognition

Project revenues are recognized as milestone obligations are completed and invoiced by the Foundation. The Foundation's revenues are derived from research and report production. All other revenues are recognized when earned.

The contracts involve multiple performance obligations and the total contract price is allocated based on the standalone selling price of the services. The standalone selling prices are based on prices established by the Foundation for services and report production. The Foundation recognizes contract revenue at a point-of-time upon completion of the work. Contracts entered into but not complete as of December 31, 2023 and 2022 were $4,199,048 and $340,069, respectively.

Revenues, receivables and contract liabilities (deferred revenue) balances are disaggregated as follows for the years ended December 31:

	2023	2022
Work for hire	$ 544,490	$ 991,389
GPRO products	51,955	69,189
Data subscriptions	-	20,000
Other income	-	207
Total contracts with customers	$ 596,445	$ 1,080,785

	Receivables		Contract Liabilities (Deferred Revenue)	
	2023	2022	2023	2022
Beginning of year	$ 6,926	$ 500	$ 91,371	$ -
End of year	$ 5,673	$ 6,926	$ 3,929,113	$ 91,371

Note 9: Leases

The Foundation entered into right-of-use operating leases for office space. Right-of-use (ROU) assets and lease liabilities are recognized at January 1, 2022, the adoption date of ASU 842. Lease liabilities are based on the present value of future lease payments over the expected lease terms. The Foundation has elected the option to use the risk-free rate determined using a period comparable to lease terms as the discount rate for leases where the implicit rate is not readily available. The risk-free rate option has been applied at 0.80% and 0.59% for the years ended December 31, 2023 and 2022. ROU assets and liabilities as of December 31, 2023 and 2022 are presented as separate line items on the Foundation's statements of financial position.

The lease term and discount rate are as follows as of December 31, is as follows:

Note 9: Leases, continued

	2023	2022
Right-of-use operating leases remaining terms	2 years	5 years
Right-of-use operating leases discount rate	0.80%	0.59%

Lease expense for lease payments is recognized on a straight-line basis over the lease term. The components of lease expense are as follows for years ended December 31:

	2023	2022
Right-of-use operating:		
Operating lease expense	$ 59,412	$ 59,412
Total lease expenses	$ 59,412	$ 59,412

Cash paid for amounts in included in the measurements of lease liabilities as of December 31, is as follows:

	2023	2022
Operating cash flows for operating leases	$ 37,716	$ 37,716

The following table summarizes the maturity of right-of-use lease liabilities under operating leases for subsequent years as of December 31, 2023:

2024	$ 91,956
2025	25,701
Total lease payments	117,657
Less: interest	(29,247)
Total lease liabilities	88,410
Less: current portion, lease liabilities	(69,537)
Long-term portion, lease liabilities	$ 18,873

Note 10: Concentrations

The Foundation receives a majority of its revenue from contributions and revenue contracts. For the years ended December 31, the Foundation received the following as percentages of total revenue:

	2023	2022
Support revenue	$ 139,130 (19%)	$ 157,936 (13%)
Revenue from customers	$ 544,490 (81%)	$ 991,389 (80%)

Of the support revenue, four and one funders represent 87% and 94% in 2023 and 2022, respectively. Each of the for funders in 2023, account for more than 10% of the support revenue. Of the revenue from customers, one customer represents 49% and 61% in 2023 and 2022, respectively, and an additional customer represents 8% and 5% in 2023 and 2022, respectively.

Note 11: Employee Benefit Plan

Effective in 2012, the LLC adopted a profit sharing and safe harbor 401(k) plan for substantially all employees of the LLC. Effective in 2017, the Plan was amended to include all employees of the Foundation. The Plan allows employees to defer a portion of their compensation, subject to certain limits, as a salary reduction contribution. The Foundation makes safe harbor matching contributions of 3% of plan compensation. The Foundation may elect to make discretionary contributions, discretionary matching contributions, and qualified nonelective contributions to employees employed on the last day of the Plan year who have completed 1,000 hours of service. All contributions made by the Foundation are fully vested when made. The Foundation’s contributions for the years ended December 31, 2023 and 2022 were \$14,228 and \$14,843, respectively.

Note 12: Prior Period Adjustment

The Foundation noted a transaction for the LLC was improperly recorded as revenue in the Foundation’s accounts receivable and revenue in 2021. Consequently, a prior period adjustment was recorded to decrease \$188,400 in receivables, related support and net assets in 2022.

Note 13: Evaluation of Subsequent Events

The Foundation has evaluated subsequent events and transactions for potential recognition or disclosure through the date at which the financial statements were available to be issued, which is the date of the independent accountants’ review report. Refer to Note 7 above that describes the lease amendment that occurred in 2024.